Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
The company has been sold to Shinshin Pharmaceuticals
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated
